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Abstract
Several mysteries surround the structure and function of the nitric oxide synthases (NOS). The NOS
oxygenase domain structure is unusually open with a large area of solvent that could accommodate an
unidentified ligand. The exact mechanism of the two-step five-electron monoxygenation of arginine
to N
G-hydroxy-L-arginine, thence to citrulline and nitric oxide (NO), is not clear, particularly as
arginine/N
G-hydroxy-L-arginine is bound at a great distance to the supposed catalytic heme Fe [III],
as the anti-stereoisomer. The Return of the Scarlet Pimpernel Paper proposed that cobalamin is a
primary indirect regulator of the NOS. An additional direct regulatory effect of the ‘base-off’
dimethylbenzimidazole of glutathionylcobalamin (GSCbl), which may act as a sixth ligand to the
heme iron, promote Co-oriented, BH4/BH3 radical catalysed oxidation of L-arginine to NO, and
possibly regulate the rate of inducible NOS/NO production by the NOS dimers, is further advanced.
The absence of homology between the NOS and methionine synthase/methylmalonyl CoA mutase
may enable GSCbl to regulate both sets of enzymes simultaneously by completely separate
mechanisms. Thus, cobalamin may exert central control over both pro- and anti-inflammatory
systems.
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Introduction
Over the past 50 years there has been a growing awareness among clinicians and
researchers that cobalamin (Cbl), vitamin B12, in all its forms, has powerful effects in
inflammation, for a diverse range of pathologies, chronic and acute. Yet, in spite of some
notable research demonstrating, for example, that Cbl directly controls the key
inflammatory cytokines tumour necrosis factor alpha (TNFa) [1] and interleukin 6 [2],
the growth factors epidermal growth factor (EGF) [1] and nerve growth factor (NGF) [3]
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DOI: 10.1080/13590840701791863and, moreover, that Cbl modulates immunity through its effects on CD8+ T lymphocytes and
natural killer cell activity [4,5], the exact mechanism of these actions remained a mystery. In
two previous hypothesis papers, A Scarlet Pimpernel for the Resolution of Inflammation? [6]
and The Return of the Scarlet Pimpernel [7], the latter partly based on novel, supportive
research findings [8], I proposed a possible answer. Cbl regulates inflammation by regulating
nitric oxide (NO), not, as had previously been thought, by simply acting as an NO ‘mop’, or
antagonist, but by regulating NO production and its safe deployment [6–8],t h r o u g ht h e
regulation of all three nitric oxide synthases (NOS), constitutive endothelial and neuronal
NOS, (eNOS, nNOS) and inducible NOS (iNOS), while simultaneously, in a mutually
responsive complementary manner, regulating key antioxidant systems. Cbl does this
indirectly, by promoting the synthesis of NOS substrates and cofactors, heme, arginine,
tetrahydrobiopterin (BH4), the nucleotides FAD/FMN and NADPH [7] and also glutathione
(GSH) status, which is ultimately dependent on Cbl status [7,9,10]. A deficiency of any
substrates or cofactors results in ‘uncoupled’ NOS reactions, decreased NO production, and
increased or excessive O2
2,H 2O2,O N O O
2 and other reactive oxygen species/reactive
nitrogen species (ROS/RNIS), leading to pathologies of unresolvable inflammation. Cbl-
promoted GSH in turn favours the formation of more benign NO species, s-nitrosothiols, and
reverses, or modulates, the effects of nitrosylation in cell signal transduction.
The marriage of GSH and Cbl results in the formation of glutathionylcobalamin (GSCbl),
formed immediately on cell entry from H2OCbl
+ and reduced GSH [11]. GSCbl is a
particularly stable intermediate postulated as participating in the formation of the B12
coenzymes methylcobalamin (MeCbl) and adenosylcobalamin (AdoCbl) [12]. No intracel-
lular role has otherwise been established for GSCbl. However, its remarkable stability and
increased, but controlled, rate of formation in inflammation [11] suggest that GSCbl may
have other intracellular roles and targets than the two Cbl coenzymes methionine synthase
(MS) and methylmalonyl CoA mutase (MCoAM). New evidence suggests that GSCbl in
particular can selectively promote iNOS and support eNOS NO formation in the early stages
of inflammation [8]. Such GSCbl promotion of iNOS and eNOS NO production in the pro-
inflammatory phase is seenas a positive event, increasingtheefficacy of theimmune response
[7] while mitigating damage to the host by lowering TNFa [7,8], for example, and eventually
signalling resolution and consequent selective inhibition of iNOS and Nuclear Factor Kappa
B (NFkB) [7]. Old, overlooked evidence also suggests that in extreme nitrosativeor oxidative
stress, GSCbl can regenerate activity of enzymes important for eventual resolution, such as
glucose 6 phosphate dehydrogenase, which ensures NADPH supply, and of lactate
dehydrogenase, aconitase and cytochrome c oxidase [7,13].
It seems probable then that GSCbl is more than a go-between that amplifies the
formation of MeCbl and AdoCbl in MS and MCoAM catalysis [14]. Perhaps GSCbl may
have a role as a ‘border guard’, packaging Cbl in a way analogous to the safe packaging of
NO by GSH or other thiols such as S-nitroso-glutathione (GSNO) [15–18] or GSCbl may
prevent intracellular NO–H2OCbl direct interactions that could have undesirable
consequences [7]. Pointedly perhaps, the binding affinity/formation constant of GSCbl
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+ interaction. Furthermore, intracellular H2OCbl would have
the potential to inactivate the two Cbl coenzymes [20,21]. It is true that in ex vivo chemical
studies, GSCbl has been shown to interact with NO, apparently yielding Cbl (III)-
NO
2+GS
N (gluthationyl radical), although the latter product was not actually verified [19].
However, this reaction was promoted by a ratio of NO 10–20 times higher than GSCbl,
which may not be representative of in vivo discrete, intracellular compartment, unbound
Cobalamin in inflammation III 213NO to GSCbl ratios. Moreover, this, and similar studies that subscribe to the Cbl as an NO
‘mop’ paradigm, used to ‘explain’ vasoconstrictor effects of Cbl, may not quite fit the more
complex biochemical relationships between Cbl, GSH and NO. GSH, for example, is
present in cells at an order of magnitude six times greater than Cbl, a ratio that appears very
tightly controlled, and may discourage competition for NO by Cbl. The vasoconstrictive
effects of Cbl may equally well be the indirect result of its fundamental promotion of GSH
[7], which in turn has a very strong affinity for NO to which it binds, continually reversing
the effects of nitrosylation in diverse systems and cell signal transduction. This would
include the regulation of vasodilation.
Of course, this postulate may be wrong, or the interaction of GSCbl with NO may, if it
occurs endogenously, have some other as yet undefined role. It has also been suggested that
GSCbl may act as a reservoir for intracellular Cbl III [22]. This is a possibility. However,
GSCbl may also exist as a modest reservoir for GSH to recombine with NO, as needed,
thereby modifying NO’s effects towards positive outcomes, if the balance between s-
nitrosothiols and RNIS shifts too far towards the latter. Perhaps this even occurs in the very
process of NO formation? Hence, perhaps the paradox of GSCbl’s increasing formation
rate constant with decreasing pH, alongside an increasing equilibrium constant with
increasing pH? [11]. Perhaps too GSCbl may provide this GSH for NO modulation in
protein regions not accessible to unbound GSH itself?
The mention of GSCbl and protein accessibility brings us to an interesting unanswered
question: whether GSCbl forms any kind of protein link outside the catalytic interactions
with the Cbl coenzymes MS and MCoAM? This hypothesis will sketch the brief outline of a
wildly speculative idea, which may prove to have a chemical basis. The scheme presented in
The Return of the Scarlet Pimpernel [7] suggests how Cbl, via its two coenzymes, is
responsible for the supply of all the substrates and cofactors of the NOS, and in the process
also keeps the redox balance and promotes the more benign species and effects of NO, and
thereby indirectly regulates the NOS. A recurrent theme of this new paradigm shows Cbl
acting as a ‘back-up disc’ for biological systems. Is it possible that Cbl may have a potential
direct regulatory interaction with the NOS and that such a direct as well as indirect,
regulatory interaction might serve to enhance or, once more, back-up or modulate the
effects of the various primary promoters and inhibitors of the three NOS? Is it possible
perhaps even that the corrin macrocycle can stand in for the porphyrin in the NOS heme
protein, which might serve principally as a template, or back-up for the corrin? And that it
is the Co that is involved in the oxidation of arginine and N
G-hydroxy-L-arginine (NHA)?
The relatively open ‘baseball mitt’ structure of the NOS oxygenase (NOSox) domain and
the funnel-shaped active channel might be designed to fit in both the two porphyrins and
the two catalytic corrins. The increased arrival of Cbl intracellularly in inflammation [6]
and the increased rate constant but controlled formation of GSCbl [7,11] may be partly to
this end. Is it also just coincidental that Transcobalamin II receptors (TCIIr) expression is
increased by interferon b [7], and that without IFNa/b iNOS NO production declines
considerably? [23] One, perhaps rather fanciful, possibility may be a direct link of GSCbl
with the dimethylbenzimidazole (DMBI) ‘base-off’ to the Co and ‘base on’, via the N
3 of its
imidazole, to the heme, as a sixth iron ligand in the NOSox domain.
NOS structures
The structures of the three NOSox domains, solved by X-ray crystallography and limited
proteolysis [24–29] are so similar to each other that drug designers who subscribe to the
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selectively inhibited. It may be likely, however, that this homology is not accidental, from
the point of view of endogenous regulation of the NOS. Rather, this homology might
suggest that the endogenous regulator could be like a single key that fits similar but slightly
different locks, the key being the DMBI of GSCbl, and the locks the NOSox domains. But
there are, in fact, some slight structural differences between the three individual NOSox
and the three individual NOS reductase domains, which may alter the effects of the DMBI
key, so that it promotes some NOS and inhibits others. Interestingly, the main difference in
the NOSox is not between the inducible and constitutive NOS, but between nNOS, on the
one hand, and eNOS and iNOS, on the other. This grouping difference is already apparent
in the NOS’s molecular weight, with nNOS at 165kDa and eNOS and iNOS almost
identical at 133 and 131kDa, respectively [30]. (Intriguingly, these weights are close to the
two Cbl coenzymes: MS 136kDa [20] and MCoAM 150kDa [21].) The NOS gene
structure and size also indicates this division: nNOS, 29 exons/28 introns, complex
structural organization and locus over a region of .200kbp; eNOS, 26 exons/25 introns,
21–22kbp; iNOS, 26 exons/25 introns, 37kbp. The overall primary domain structure with
amino acid residue sequence positions for the individual substrates and cofactors of the
three NOS may be seen in Figure1. The cysteine residue ligating the heme to the
calmodulin (CaM)-binding site is highlighted in all three NOS, and here again there is a
difference between nNOS ligation at Cys419 and eNOS/iNOS at relatively close Cyst184
and Cyst200, respectively. The amino acid loop insert in the middle of the eNOS/nNOS
FMN binding reductase domain, however, differentiates them from iNOS. This loop is
thought to be auto-inhibitory [31] and acts by destabilizing CaM binding at low Ca
2+
concentrations and thus inhibits electron transfer from FMN to heme, in the absence of
Figure 1. Human neuronal (nNOS), endothelial (eNOS) and inducible nitric oxide synthase (iNOS) domain
structure (PDZ domain, named after homologous domains in three proteins: PSD-95, DH/g, ZO-1).
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2+/CaM binding [30]. As discussed previously, individual NOS reactions that catalyse
the five electron monoxygenation I and II processes involved in NO production are more or
less ‘coupled’ in respect of reduction by the flavins and NADPH [7]. A study of all three
isoforms using the artificial electron acceptor, cytochrome c, and comparing them with
NADPH-cP450 reductase-catalysed cytochrome c reduction, showed minimal turnover for
eNOS/nNOS in the absence of Ca
+/CaM. On addition of Ca
+/CaM nNOS showed a 10- to
15-fold increase in cytochrome c reduction, 1.6 times the rate of NADPH-cP450 reductase
reduction. Although eNOS cytochrome c reductase activity increased by more than two-
fold, on Ca
2+/CaM addition, its activity was only about 16% of the NADPH-cP450
reductase. iNOS, in the absence of Ca
2+/CaM catalysed cytochrome c reduction at the
same rate as nNOS+Ca
2+/CaM [32]. This gives a ranking for the individual isoform
reduction potentials: iNOS5nNOS&eNOS [32]. Another study in which electron transfer
to the heme oxygenase domain was measured by reduced CO difference spectroscopy,
which requires reduced heme, found that eNOS was the most ‘tightly coupled’ isoform,
with NADPH reducing the heme as much as dithionite, much superior to the 70%
reduction of heme by nNOS and 30% by iNOS [32]. Other non-structural differences
between the constitutive and inducible NOS may also have a bearing on potential
regulation by GSCbl and its DMBI. Dimer assembly in iNOS appears to involve only the
oxygenase domain, whereas in eNOS/nNOS it involves interactions, within the reductase
domain, and between the reductase and oxygenase domains across the dimer [30]. iNOS is
consequently more dependent on BH4 binding for its dimeric assembly than eNOS/nNOS
[33]. BH4 in the iNOSox folds the central interface region in a novel ab fold, to create a
30A ˚ -deep, funnel-shaped active-site channel and tilt the heme so it is available for
interactions with the reductase domain [30] (Figure2). All three NOS, of course, also
require insertion of heme [34] and binding of the L-arginine substrate, as well as the
cofactor, BH4, for dimerization and activity, and so, setting aside the structure of NOS
isoforms and their internal oxidation reduction kinetics, individual NOS binding affinity for
L-arginine might also be relevant to how GSCbl and its DMBI may intervene, as may slight
variations in the accessibility of the heme, which is buried deep in the protein’s interior in
the distal pocket, making extensive van der Waals interactions with hydrophobic and
aliphatic side chains. So there is little solvent accessibility to the heme, except for one of its
propionates, and a large, 750A ˚ 3 [33] substrate/cofactor access channel, which allows
solvent access to both the active site, heme and BH4.
Imidazoles and NOS promotion/inhibition
The hypothesis that the GSCbl DMBI may have the potential to directly regulate the NOS
is drawn from studies of compounds that promote or inhibit NOS, specifically imidazoles
and N
1-substituted imidazole derivatives or analogues, which, like CO, NO, CN, have the
capacity to bind directly to the pentacoordinate heme iron as a sixth ligand, preventing O2
binding [24,35–39]. Arginine, a bulkier molecule with non-bonded electrons, does not
directly bind to the heme iron, but binds to the protein in a network of hydrogens, near the
distal heme pocket, and lies with its central N-guanidine, 3.8A ˚ away from, and coplanar to,
the heme [30,40]. X-ray crystal data show that this dense network of hydrogen bonds
orients L-arginine and NHA rigidly in relation to the heme, so that NHA is bound as the
anti-stereoisomer, with its hydroxylimine oxygen and guanidinium carbon distant from the
iron (4.3 and 4.4A ˚, respectively) [40]. Moreover, the porphyrin ring is in a non-planar
concave configuration, with the bowl facing into the NOS distal pocket, where the heme is
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heme in peroxidases [33], which utilize a histidine residue as the proximal ligand. The
iNOS crystal structure reveals that the heme plane facing the proximal thiolate ligand is
flipped 180u, exactly opposite to that in cP450s with which otherwise NOS share certain
similarities, such as NADPH, FAD/FMN and monoxygenation [24]. The positioning of
NHA so far from the heme iron poses a puzzle in respect of its aerobic oxidation to
citrulline and NO, because this oxidation reaction requires three electrons but consumes
only one NADPH reducing equivalent and apparently, although not conclusively, one from
NHA. It is also not clear whether the NOS FeIII heme is reduced by NHA or the NADPH-
derived reducing equivalent to initiate the second step [40]. The bulk of the evidence
suggests that NHA cannot reduce FeIII heme [40]. X-ray crystal data also preclude direct
ligation of NHA to FeIII heme [40]. The source of the missing electrons is not clear, and
both a nucleophilic hydroperoxo-Fe(III) heme, the oxenoid species,(oxo-Fe(IV)(PN
0+)o f
P450 oxygenase reactions, or a radical-type auto-oxidation mechanism have been proposed
as the oxidizing intermediates, but none has yet been definitively confirmed [40].
Figure 2. Model of nitric oxide synthase oxygenase (NOSox) dimer with approximate scheme for hypothetical
glutathionylcobalamin (GSCbl) links in relation to the two hemes, ZnS4,B H 4, arginine. Ser 104 is in the loop with
the Cys ligands and H bonds to the C6 side chain of BH4.
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molecules of imidazole can bind within the heme distal pocket, one ligating the heme iron
and the other the carboxylate of murine Glu 371, and Glu 377 of human iNOS, which also
binds L-arginine’s guanidino nitrogens [24,38]. Imidazole and I-phenylimidazole promote
iNOS dimerization at the same rate as L-arginine and BH4, suggesting that there are two
ways of promoting iNOS dimerization [35]; firstly by a direct FeIII
+ interaction of
imidazoles, or relatively simple, non-bulky imidazole, such as I-phenylimidazole derivatives,
which have an accessible N
3, that ligate the heme iron, followed by L-arginine, BH4
promoter binding. Alternatively, by initial substrate and promoter, L-arginine, BH4 binding,
followed by productive subunit dimeric interaction involving imidazoles [35]. These
imidazoles are small enough and hydrophobic enough to fit into the heme distal pocket, and
are strong true heme ligands, which produce a type II low-spin heme spectrum with Kd in
the millimolar range [24,39]. (L-arginine and BH4 after bonding to the heme protein can
effect a gradual shift to the five co-ordinate high-spin heme.) Dimethylimidazole also has
such an effect [24,37–39]. The question is: can GSCbl’s DMBI do this to some degree?
(The bulky benzene ring may modulate matters.) If it can also act as a sixth FeIII
+ ligand,
the DMBI may in effect prevent the FeIII
+ heme from being reduced, thus presenting the
possibility that the Co in GSCbl can be reduced in its place.
The discovery that there are two ways of promoting iNOS dimer assembly at the same
rate might tie in with the idea that GSCbl and its DMBI may play a regulatory back-up role
in the NOS dimer assembly, or, indeed, a central one in catalysis. In the former scenario,
for instance, if arginine is relatively low, due to diet or other factors, a direct effect of GSCbl
on iNOS dimer assembly, with some degree of interplay between the above-mentioned two
modes of dimer assembly, might maximize the impact of well-coupled, relatively low L-
arginine. If one subscribes to The Return of the Scarlet Pimpernel hypothesis’ view of the
importance of good iNOS function and higher NO production in inflammation, this back-
up role of the DMBI could be critical in acute immune defence scenarios, preventing
pathologies of unresolvable inflammation, and also in non-acute scenarios such as in the
maintenance of the protective functions of continuously active iNOS in lung and retina [7].
Such a mechanism would also have implications for the sustained promotion of eNOS in
inflammation, where there may be increased competition between eNOS and iNOS for L-
arginine. In other words, it would enable GSCbl’s DMBI to simultaneously promote both
iNOS and eNOS. nNOS is in a class by itself because it appears that imidazoles
paradoxically inhibit nNOS [39], just as they do cP450 and catalase [41]. This inhibition of
nNOS is non-competitive with arginine and BH4, and negatively impacts on Ca
2+/CaM-
dependent consumption of NADPH [39]. By contrast, in eNOS, L-arginine binds in a
manner competitive to imidazoles, including 2-methylimidazole and 4-methylimidazole
[37]. Such variations in binding affinity of the two Ca
2+/CaM binding dependent NOS for
the arginine substrate and imidazoles, or the varied degrees to which these enzymes are
coupled, together with slight structural variations in their oxygenase domain, the different
cysteine residues (cys419, cys184) that ligate the heme to the Ca
2+/CaM binding site in
nNOS/eNOS for example, or known slight variations in each of the auto-inhibitory loops of
eNOS/nNOS flavins in the reductase domains, or of the C-terminal tails of all three NOS,
which differently regulate electron flow [31,40,42,43] or, again, variable N-terminal
domain swapping affecting the size of dimer interfaces [31,43], might all explain how two
such homologous isoforms may be differently regulated by the same agent. Moreover, it
might be that iNOS alone may be regulated by Co-oriented oxidation of arginine/NHA,
whereas eNOS/nNOS are catalysed as traditionally understood, via FeIII
+ reduction.
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The DMBI of MeCbl and AdoCbl surprised B12 chemists’ expectations for its proposed
role in Cbl coenzyme catalysis, by turning out to be base-off to the Co in the respective MS
and MCoAM enzymes [20,21,44]. It had been surmised that the DMBI of MeCbl and
AdoCbl would play a role in the coenzyme-bound state where it would directly control the
reactivity of their upper axial ligands. Instead, in both cases the Co swaps the DMBI for a
link to the N
2 of the imidazole of both proteins’ histidine residues, 759 and A610,
respectively, thus allowing the proteins to modulate substrate reactivity [20,21,44].
Meanwhile, the DMBI is extended and bound deep in a narrow hydrophobic pocket
between the b-sheet and the C-terminal helix of the respective proteins [20,21]. To B12
chemists this appeared almost useless, a mere ‘anchor’. But what if it is, in fact, a firmly
sheathed sword? Both MS and MCoAM are activated by reduction of their respective Cbls,
whose upper axial ligands form highly reactive carbon–cobalt bonds that are easily cleaved.
This lability has a distinct relationship to the length of the lower Co–N axial ligand, with
the highly reactive alkyl-Co bonds of Me and Ado having longer lower axial bonds
(2.20¡0.03R2.21A ˚ ), whereas more stable Cbls with strongly bonded upper axial ligands,
such as CN or OH, have somewhat shorter Co–N bonds to the lower axial ligand
(2.15¡0.03A ˚–2.14¡0.03) [45,46]. The notably stable intermediate, GSCbl, of course,
falls into the latter category (2.15¡0.03A ˚) [46]. If we posit that GSCbl has a back-up, or
supplementary, modulatory role, or even a central role, which involves some direct
interaction with the NOS isoforms, this interaction will probably differ from that of MeCbl/
AdoCbl with MS/MCoAM, as GSCbl is considerably less reactive.
Before the structures of MeCbl/AdoCbl bound MS and MCoAM were elucidated, B12
chemists were expecting to find globin or nucleotide-binding folds in the proteins [20],
because of the analogy between the porphyrin of heme and the corrin. In the event, MS and
MCoAM showed little homology with proteins that bind heme or nucleotides.
Nevertheless, perhaps the true home of Cbl’s so-called ‘false’ nucleotide, the DMBI, is
actually in the NOS heme proteins, deep in a hydrophobic region of the NOS distal heme
pocket, and the difference in homology between the enzymes is important because it
enables Cbl to affect and regulate both sets of proteins without mutual interference. It is
clear also that different Cbls have different biological effects, for all the many different
reasons hitherto discussed [7]. But GSCbl is a go-between. In this hypothesis it may
simultaneously modulate both sets of proteins, decreasing or increasing the activity of MS
and MCoAM together with the formation of MeCbl and AdoCbl to balance the effects of
its early promotion of NO in inflammation, a promotion that may be both indirectly
modulated as discussed in The Return of the Scarlet Pimpernel [7], or directly modulated
by GSCbl’s base-off DMBI possibly extended in a new conformation, in the funnel of
iNOSox/eNOSox domains with the N
3 of the imidazole then ligating the heme (Figure2).
Even the established ‘upward’ deformation of the corrin ring found in short Co–N bonded
Cbls [45], such as GSCbl, might facilitate the fit with the funnel shape of the NOSox
dimer, where the corrin ring might lodge parallel to the porphyrin of the heme down below.
This upward deformation of the corrin macro-cycle may be a mimic of the porphyrin’s
concave bowl, above which it may lie, linking the FeIII below with the N
3 of the DMBI,
while the Co is almost offered to BH4. Given that the NHA, like its precursor arginine, is
bound at a great distance to the heme iron, as the anti-stereoisomer, in this scenario it
would, in fact, be facing, and closer to the corrin, like BH4, and this may be of some
significance. The substrate arginine restricts O2 binding, and Raman data show that bound
O2 points away from the substrate [47]. Thus, the distal oxygen of theoretically FeIII
+
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orientation and distance between Fe(III) heme and guanidinium carbon do not favour a
proposed peroxonucleophilic attack [40]. It is once more tempting to speculate whether it
is not GSCbl that completes the cryptic oxidation of NHA to citrulline and NO? Maybe
GSCbl can partially stand in with NADPH as a reducing equivalent? If this were so, a
deficiency in Cbl would definitely result in uncoupled NOS reactions, quite apart from the
impact of Cbl degrees of deficiency on supply of substrate and cofactors, the absence of
which also uncouples the NOS [7]. Ligation of the heme FeIII by GSCbl’s DMBI may
prevent heme activation and act as a signal, facilitating the reduction of GSCbl to Cbl II
instead, followed by activation of O2 in tandem with BH4, so that NHA is generated from
arginine, and then complete oxidation of NHA to NO and citrulline occurs.
Catalysis of NOS, cP450, MS and MCoAM
Since the observation of the radical species of BH4,B H 3, in NOS, the hypothesis was
hitherto advanced that a non-heme metal ion, possibly a non-heme iron, might be the
intermediate that catalyses oxidation of L-arginine to NHA [48] in analogy to BH4-
dependent amino acid hydroxylases, and that because BH4-free NOS makes NO
2, not
NO
N, and does not catalyse any reaction with bound arginine, BH4 must participate in some
way in l-electron chemistry [48]. (Among the candidate metals, Co
3+ was found to be
inhibitory, but this may not detract from the GSCbl hypothesis as the Co
3+ was deployed as
aC l
2+ salt [49], a simple compound that would bear little relation to the structural
complexity and consequent effects of Co
3+ in GSCbl.) This less orthodox view had been
challenged, both by the discovery that 5-methyl BH4 supports the NOS reaction, but not
O2 activation, and by laser atomic emission, metal ion analysis, which shows the only
metals present in NOS are calcium, zinc and iron. This analysis, however, was done in
isolated eNOS mutants. Similarly, another analysis of the NOSox crystal structure that
showed no non-heme iron, or other transition metals, bound was carried out with a His-tag
fusion protein purified by an Ni resin, and consequently exposed to a high concentration of
imidazoles, which would prevent any such binding [25]. The structure of the NOSox active
channel shows a large area (750A ˚ 3) of solvent, which it has been surmised may
accommodate an as yet unidentified ligand. This leaves room for the GSCbl hypothesis.
Moreover, even with respect to monoxygenation I, the hydroxylation of L-arginine to NHA,
the evidence for the participation of the heme iron is indirect. It is an assumption made
largely from its presence in the enzymes, essential for dimerization, and by analogy to the
heme role in cP450 catalytic reactions, an analogy further prompted by the sequence
homology of NOS and cP450 reductase domains, and shared FAD/FMN content. Yet, if
one posits GSCbl as the catalyst in NOS monoxygenations I and II, it may be that the two
heme irons are in fact principally anchors for GSCbl, and that a non-heme iron is involved
in monoxygenation I, and the Co
3+ of GSCbl is involved in monoxygenation II.
Alternatively, it is also conceivable that the heme iron is involved in monoxygenation I
and is cyclically deactivated by GSCbl’s DMBI so that the Co
3+ can complete
monoxygenation II, then, as the NO displaces the DMBI from the heme iron, the process
begins again.
There is also a possibly fruitful, Cbl enzyme analogy to be made with respect to NOS
BH4 and GSCbl. In MS catalysis, MeCbl is bound to residues His 757, Asp 75, which are
protonated. Deprotonation promotes demethylation and the formation of the radical, Cbl
I, and deprotonation of His 757 also increases the nucleophilicity of Cbl I to facilitate its
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5-methyltetrahydrofolate [20] and consequent methylation of Cbl I to MeCbl
III, a cyclical process. N
5-methyltetrahydrofolate (NMTHF) is a pterin family member,
like BH4. Maybe GSCbl III in the NOS is able to harvest an electron from BH4 then return
it following NHA hydroxylation? If so, this may be the reason for the observed BH4–BH3
recycling, which has always mystified. In yet another analogy, His and Asp residues 610
and 608, respectively, are also important to MCoAM AdoCbl binding and catalysis [21],
and therefore it may be worth investigating if the equally close spatially related His 652,
Asp 650 in the vicinity of BH4 in NOS may be similarly a potential binding site for GSCbl
with equal, hypothetical, catalytic potential.
The benzene ring and dimethyl residues of the DMBI may, as noted earlier, have some
steric modulatory effects in the active site channel that result in the DMBI being less
strongly inhibitory — for nNOS — and/or less strongly promotional — for iNOS, eNOS —
than simple imidazoles. In this general scheme, the GSH of GSCbl may also be proximal to
the surprising zinc tetrathiolate bridge at the bottom of the dimer interface, 21.6A ˚ from
each heme, and 12A ˚ from each BH4 site, that plays a structural role in NOS quaternary
architectural assembly, protects the BH4 binding site and possibly provides a docking site
for the reductase domain, as the Zn is a strongly positive electrophile [33,50]. This role may
be deregulated by known NO ejection of zinc and/or modulated by the formation of
disulphide bonds between the symmetry-related cys 115 residues [48–50]. The
hypothetical proximity of the GSH in NOSox bound GSCbl (Figure2) could enable it
to keep the zinc bound for activity, and prevent deactivation, by inhibiting disulphide
bridge formation, a function that could equally well be accomplished by free GSH perhaps,
assuming it had access, which it may not. Of course, the solvent is also a strongly reducing
environment, and the GSH of GSCbl may instead have a role in modulating the balance of
NO species production in NOS, consistent with its global role of (Cbl-supported) GSH
NO packaging discussed previously [7]. Alternatively, the possibility exists that the GSH of
GSCbl may form a triad relationship with the zinc and cysteine residues that modulates the
rate of NO production and/or release. Nitrosation reactions at thiol residues co-ordinated
to metal centres are seen as possible functional switch mechanisms [50]. (This has
implications for Cbl–GSH regulation of transcription factors that contain zinc in their
DNA-binding domains, for example, the zinc finger of NFkB.) Moreover, cyclic activation/
deactivation of the zinc tetrathiolate by NO/GSH might be synchronous and linked to Cbl
III/Cbl II–BH4/BH3 cycling during NO production. (This would have some analogy to Cbl
III–Cbl I recycling during MS catalysis.) The latter possibility may exist because one of the
zinc ligands, Cys 101, is only two residues away from Ser 104, which H-bonds directly to
the BH4 hydroxyl side chain [33] (Figure2). Moreover, Val 106 of the polypeptide chain
forms a direct unbonded contact with BH4. Thus, it has been concluded, that any
disruption of the zinc or its ligands will result in distortions of this region of the polypeptide
chain, diminished affinity for BH4 and arginine binding, and loss of protein stability and
catalysis [33]. Also of possible relevance to the putative GSCbl/BH4 relationship is the
demonstration that a thiol, and an inhibitor of the NOS, S-ethylisothiourea, is
paradoxically able to promote BH4 binding, and, in the absence of BH4, binding of the
structurally analogous arginine [51]. This finding hints at the possibility that the GSH of
GSCbl, although not an inhibitor, may as a thiol have an identical endogenous role, with
respect to BH4 binding.
As GSCbl elsewhere in the cell would also be simultaneously promoting AdoCbl and
MCoAM to counter the potential negative effects of NO overproduction, it would
eventually ensure the arrival of increasing amounts of arginine and BH4, which could then
Cobalamin in inflammation III 221displace GSCbl’s DMBI, in the first ‘back-up’ scenario. Alternatively, in the latter, more
central scenario, the DMBI may eventually be displaced by NO when it begins iNOS
inhibition, in keeping with the view of GSCbl as the catalyst of NHA oxidation, outlined
above. Final NO ejection of the zinc, and reformation of GSCbl (III), may then lead to
iNOS dimer degradation. Thus, it may be that the CoIII in the corrin ring can stand in for
the FeIII in the porphyrin ring, which it so closely resembles. (Whereas the DMBI may
regulate NO and vice versa, as NO is remarkable among small molecules for its ability to
displace trans-imidazole ligands.) This scheme is very roughly sketched out, with much fine
structural and mechanistic detail unknown and still to be adumbrated, if proven. For
perhaps, after all, this latest of the three Cbl hypotheses is just a redundant fantasy. Or
perhaps not. Absence of proof is not proof of absence. According to legend, the Scarlet
Pimpernel was very elusive indeed.
Testing the Scarlet Pimpernel hypotheses
A Scarlet Pimpernel for the Resolution of Inflammation? [6] discusses aspects of testing the
general hypothesis that Cbl plays a central immunoregulatory role, in the clinic, for
systemic inflammatory response syndrome/sepsis/septic or traumatic shock. Since its
publication, some pre-clinical studies have already been performed [8] and more are
underway. However, as The Return of the Scarlet Pimpernel [7] has reformulated and
expanded the original hypothesis, focussing it on Cbl central regulation of the NOS and
complementary regulation of key antioxidant systems, it is clear that, if there is truth in this
new paradigm, there may be some very widespread and significant implications not only for
the treatment of pathologies of unresolvable inflammation such as sepsis, but for other
intractable disease, such as malaria, HIV, diabetes, antibiotic-resistant tuberculosis,
Alzheimer’s disease, methicillin resistant Staphylococcus aureus (MRSA), viral epidemics
and cancer, where NOS malfunction and iNOS depression may be implicated. In the
contrarian view of the ‘Scarlet Pimpernel’, there is no need to design selective inhibitors of
the NOS. Indeed, this may be a venture just as ill-fated as the clinical use of unselective
NOS inhibitors has proven to be. Instead, by using existing, relatively well-tolerated,
immune-priming drugs, principally the interferons a,b,c, and possibly certain others, such
as APO2-L-Trail, in combination with pre- and concurrent treatment with very high — up
to 5g, or over — doses of Cbl, principally perhaps GSCbl, but certainly the already
pharmacologically safe and licensed OHCbl, it may be possible to stimulate or reawaken
the native endogenous NO regulation mechanism of the immune system for resolving
inflammation. In diseases such as malaria and cancer, where parasites and tumours evade
immune surveillance and flourish by deregulating the NOS, consequently damping down
immunity, high-dose Cbl and interferon abmight prove curative, by enabling the body to
mount a strong, targeted response. As such therapy is, in the coinage of the great Linus
Pauling, an ‘orthomolecular’ approach to the treatment of disease, this treatment should be
supported with a broad spectrum vitamin, mineral, essential fatty acid supplement, and
followed up by maintenance of good nutritional and Cbl status.
However, although there are sufficient human, animal and in vitro pharmacological
safety and efficacy data on Cbl to justify clinical studies in sepsis [6], there is a need to do
considerable pre-clinical studies for the other aforementioned diseases, and equally to
investigate the substance of ‘The Return of the Scarlet Pimpernel’ and ‘The Sword in the
Stone?’ thoroughly in the laboratory. Study of the impact of Cbl, particularly GSCbl, in
both the pro- and anti-inflammatory phases of immune defence with respect to all three
222 C. WheatleyNOS and antioxidant systems has already commenced [8], but there is also a need for
detailed molecular investigation with crystallography and/or limited proteolysis of the
possible direct impact of GSCbl on all three NOSox domains. A related study might also
consider whether GSCbl’s DMBI plays a direct regulatory role in nitric oxide dioxygenases
(NODS), such as flavohaemoglobin, haemoglobin and myoglobin, which have a high
affinity for binding NO, and are, together with Cbl, also crucial to NO homeostasis by
continually combining O2 with ‘free’ NO to form inactive/non-toxic nitrate (NO3) [52]. If
direct Cbl regulation of NODS via the DMBI is indeed the case, then one might also
surmise that the antibiotic action of NO/GSNO may be further enhanced by the DMBI of
AdoCbl on TCIs released in the presence of bacteria, by analogy with the known inhibition
by imidazole antibiotics of NODS, such as microbial flavohaemoglobin [53], which contain
large hydrophobic heme pockets capable of sequestering bulky aliphatic lipids and
imidazole N
1 substituents [53]. A corollary of the foregoing arguments might also be direct,
as well as indirect, Cbl regulation of all heme proteins in a complementary manner: Cbl as
the ultimate transcription factor.
It would also be of interest to measure activity in vivo, in various pathologies of unresolved
inflammation, with and without Cbl, of key enzymes, such as, MS and MCoAM; aconitase;
cytochrome c oxidase; lactate dehydrogenase, aldolase, glucose 6 phosphate dehydrogenase
(and other glycolytic enzymes), as well as levels of serum GSH, and also to identify the
balance of NO species in inflammation, resolved and unresolvable (GSNO, albumin/NO
complexes). As mentioned earlier, some notable corroboratory pioneering studies of the
impactofCbl,orits deficiency,onthekeyinflammatorycytokinesTNFa[1]andinterleukin-
6 [2,54], as well as on the growth factors EGF [1] and NGF [3] already exist. If, as the new
paradigm and evidence suggests, such relationships are really an outcome of Cbl NO central
regulation [7], these studies should be extended in the light of this hypothesis. It may be
predicted that Cbl will also regulate most other growth factors, such as transforming growth
factor b1, essential for the resolution of inflammation, basic fibroblast growth factor (bFGF)
or vascular endothelial growth factor, which has pleiotropic Sp1, also the TCII transcription
factor, in its promoter region [55]. This might have implications for the anti-angiogenic
treatmentofcancerwith Cbl/interferon.Suchacombination mightadditionallyfullyalertthe
immune system to the presence of tumour cells that normally evade surveillance, and thus
promote endogenous existing means for tumour eradication via strong promotion of iNOS
NO production. The posited central Cbl–NO regulation as outlined in The Return of the
Scarlet Pimpernel may also provide an alternative explanation for the lack of toxicity and
efficacy of exogenous NOCbl/interferon b demonstrated in cancer [56], a study that was
critiqued in A Scarlet Pimpernel for the Resolution of Inflammation? [6] Exogenous NOCbl
was used as a vehicle for the theoretical safe delivery of NO to completely eradicate ovarian
tumours. NOCbl uptake by tumours was promoted by interferon b, which normally
upregulates TCII receptors in inflammation [56], promoting increased intracellular arrival of
H2OCbl. However, this study used no control OHCbl/interferon b and therefore cannot
prove that the impressive results attributed to exogenous NO alone were not also effected by
other Cbls endogenously [6]. Yet, there is both laboratory and clinical evidence for
therapeutic effects of high-dose Cbls — CNCbl, OHCbl, MeCbl — in cancer [4,5,57–63].
Some in vitro evidence even demonstrates that the combination of Cbl and interferon b is
synergistic in astrocyte gliosis [64]. However, no explanation of the fundamental mechanism
of such anti-oncogenic Cbl effects has been published until now.
With renewed hindsight, the extraordinary curative high doses of NOCbl injected into
mice with tumours in that study — equivalent to 12g daily for nearly 3 weeks in humans —
Cobalamin in inflammation III 223may have been rapidly converted to GSNO, and OHCbl, in the circulation, and thence to
GSCbl intracellularly, and probably also promoted additional endogenous high NO
production, as well as providing the native intracellular Cbl tools (GSCbl/AdoCbl/MeCbl)
to deploy it without host toxicity, and may, in fact, be unwitting proof of the Scarlet
Pimpernel hypotheses.
Acknowledgements
The author wishes to thank Hilary Boyd for help in the preparation of the figures and the
manuscript, Alex Lane-Wheatley for Figure2, and Professor Mauro Perretti for helpful
discussion.
References
1. Peracchi M, Bamonti Catena F, Pomati M, et al. Human cobalamin deficiency: alterations in serum tumour
necrosis factor-a and epidermal growth factor. Eur J Haematol 2001;67:123–7.
2. Scalabrino G, Corsi MM, Veber D, et al. Cobalamin (vitamin B12) positively regulates interleukin-6 levels in
rat cerebrospinal fluid. J Neuro-immunol 2002;127:37–43.
3. Scalabrino G, Mutti E, Veber D. Increased spinal cord NGF levels in rats with cobalamin (vitamin B12)
deficiency. Neurosci Lett 2006;396:153–8.
4. Sakone T, Takada S, Kotani H, Tsunematsu T. Effects of methyl-B12 on the in vitro immune functions of
human T lymphocytes. J Clin Immunol 1982;2:101–9.
5. Tamura J, Kubota K, Murakami H, et al. Immunomodulation by vitamin B12 augmentation of CD8+ T
lymphocytes and natural killer (NK) cell activity in vitamin B12-deficient patients by methyl-B12 treatment.
Clin Exp Immunol 1999;116:28–32.
6. Wheatley C. A Scarlet Pimpernel for the resolution of inflammation? The role of supra-therapeutic doses of
cobalamin, in the treatment of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and
septic or traumatic shock. Med Hypotheses 2006;67:124–42.
7. Wheatley C. The return of the Scarlet Pimpernel. Cobalamin in inflammation II: cobalamins can both
selectively promote all three nitric oxide synthases (NOS), particularly iNOS and eNOS, and, as needed,
selectively inhibit iNOS and nNOS. J Nutr Environ Med 2007;16:181–211.
8. Rachmilewitz D, Ligumsky M, Rachmilewitz B, et al. Transcobalamin II level in peripheral blood monocytes –
a biochemical marker in inflammatory diseases of the bowel. Gastroenterology 1980;78:43–6.
9. Ling CT, Chow BF. Effect of vitamin B12 on the levels of soluble sulfhydryl compounds in blood. J Biol
Chem 1953;202:445–56.
10. Register UD. The effect of vitamin B12 on liver and blood non-protein sulfhydryl compounds. J Biol Chem
1954;206:705–9.
11. Xia L, Cregan AG, Berben LA, Brasch NE. Studies on the formation of glutathionylcobalamin: any free
intracellular aquacobalamin is likely to be rapidly and irreversibly converted to glutathionylcobalamin. Inorg
Chem 2004;43:6848–57.
12. Suto RK, Brasch NE, Anderson OP, Finke RG. Synthesis, characterization, solution stability and X-ray
crystal structure of the thiolatocobalamin c-glutamylcysteinylcobalamin, a dipeptide analog of glutathionyl-
cobalamin: insights into the enhanced Co-S bond stability of the natural product glutathionylcobalamin. Inorg
Chem 2001;40:2686–92.
13. Dubnoff JW, Bartron E. The effect of B12 on enzyme activity in E. coli mutant 113-3. Arch Biochem Biophys
1956;61:99–110.
14. Pezacka E, Green R, Jacobsen DW. Glutathionylcobalamin as an intermediate in the formation of cobalamin
coenzymes. Biochem Biophys Res Comm 1990;169(2):443–50.
15. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox activated forms. Science
1992;258:1898–902.
16. Stamler JS, Jaraki O, Osborne J, et al. Nitric oxide circulates in mammalian plasma primarily as an s-nitroso
adduct of serum albumin. Proc Natl Acad Sci 1992;89:7674–7.
17. Singh SP, Wishnok JS, Keshive M, Deen WM, Tannenbaum SR. The chemistry of the s-nitroso-glutathione/
glutathione system. Proc Natl Acad Sci 1996;93:14428–33.
224 C. Wheatley18. Ji Y, Akerboom TPM, Sies H, Thomas JA. S-Nitrosylation and S-glutathionylation of protein sulfhydryls by
S-nitroso glutathione. Arch Biochem Biophys 1999;362:67–78.
19. Zheng D, Birke RL. The reaction of nitric oxide with glutathionylcobalamin. J Am Chem Soc
2002;124:9066–7.
20. Luschinsky Drennan C, Huang S, Drummond JT, Matthews RG, Ludwig ML. How a protein binds B12: a
3.0A ˚ X-ray structure of B12-binding domains of methionine synthase. Science 1994;266:1669–74.
21. Mancia F, Keep NH, Nakagawa A, et al. How coenzyme B12 radicals are generated: the crystal structure of
methylmalonyl-coenzyme A mutase at 2A ˚ resolution. Structure 1996;4(3):339–49.
22. Zheng D, Yan L, Birke RL. Electrochemical and spectral studies of the reactions of aquacobalamin with nitric
oxide and nitrite ion. Inorg Chem 2003;41:2548–55.
23. Riches DWH, Underwood GA. Expression of interferon-beta during the triggering phase of macrophage
cytocidal activation. J Biol Chem 1991;266:24785–92.
24. Crane BR, Arvai AS, Gachui R, et al. The structure of nitric oxide synthase oxygenase domain and inhibitor
complexes. Science 1997;278:425–31.
25. Crane BR, Arvai AS, Ghosh DK, et al. Structure of nitric oxide synthase oxygenase dimer with pterin and
substrate. Science 1998;279:2121–6.
26. Fischmann TO, Hruza A, Niu XD, et al. Structural characterization of nitric oxide synthase isoforms reveals
striking active-site conservation. Nat Struct Biol 1999;6:233–42.
27. Li H, Raman CS, Glaser CB, et al. Crystal structures of zinc-free and -bound heme domain of human
inducible nitric oxide synthase. Implications for dimer stability and comparison with endothelial nitric oxide
synthase. J Biol Chem 1999;274:21276–84.
28. Raman CS, Li H, Martasek P, Kral V, Masters BS, Poulos TL. Crystal structure of constitutive endothelial
nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell 1998;95:939–50.
29. Tierney DL, Huang H, Martasek P, et al. ENDOR studies of l-arginine and N-G-hydroxyl-l-arginine bound
to all three holo-nitric oxide synthase isoenzymes. J Am Chem Soc 2000;122:5405–6.
30. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function, and inhibition. Biochem J
2001;357:593–615.
31. Salerno JC, Harris DE, Irizarry K, et al. An autoinhibitory control element defines calcium-regulated isoforms
of nitric oxide synthase. J Biol Chem 1997;272:29769–29777.
32. Marta ´sek P, Miller RT, Roman LJ, Shea T, Masters BSS. Assays of isoforms of E. coli-expressed nitric oxide
synthase. Meth Enzymol 1999;301:70–8.
33. Raman CS, Li H, Martasek P, Kral V, Masters BS, Poulos TL. Crystal structure of constitutive endothelial
nitric oxide synthase: a paradigm for pterin function involving a novel metal center. Cell 1998;95:939–50.
34. Albakri QA, Stuehr DJ. Intracellular assembly of inducible NO synthase is limited by nitric oxide – mediated
changes in heme insertion and availability. J Biol Chem 1996;271(10):5414–21.
35. Sennequier N, Wolan D, Stuehr DJ. Antifungal imidazoles block assembly of inducible NO synthase into an
active dimer. J Biol Chem 1999;274:930–8.
36. McMillan K, Adler M, Auld DS, et al. Allosteric inhibitors of inducible nitric oxide synthase dimerization
discovered via combinatorial chemistry. Proc Natl Acad Sci 2000;97:1506–11.
37. Berka V, Chen PF, Tsai AL. Spatial relationship between l-arginine and heme binding sites of endothelial
nitric-oxide synthase. J Biol Chem 1996;271:33293–3300.
38. Chabin RM, McCauley E, Calaycay JR, et al. Active-site structure analysis of recombinant human inducible
nitric oxide synthase using imidazole. Biochemistry 1996;35:9567–75.
39. Wolff DJ, Datto GA, Samatovicz RA, Tempsick RA. Calmodulin-dependent nitric-oxide synthase.
Mechanism of inhibition by imidazole and phenylimidazoles. J Biol Chem 1993;268:9425–9.
40. Groves JT, Wang CC-Y. Nitric oxide synthase: models and mechanisms. Curr Opin Chem Biol
2000;4:687–95.
41. Swanson RA, Dus KM. Specific covalent labeling of cytochrome P-450CAM with 1-(4-azidophenyl)imida-
zole, an inhibitor-derived photoaffinity probe for P-450 heme proteins. J Biol Chem 1979;254:7238–46.
42. Roman LJ, Martasek P, Miller TR, et al. The C termini of constitutive nitric oxide synthases control electron
flow through the flavin and heme domains and affect modulation by calmodulin. J Biol Chem
2000;275:29225–32.
43. Masters BS. Structural variations to accommodate functional themes of the isoforms of NO synthases. In:
Ignarro LJ, editor. Nitric oxide: biology and pathobiology San Diego: Academic Press; 2000. pp91–104.
44. Sirovatka JM, Finke RG. Coenzyme B12 chemical precedent studies: probing the role of the imidazole base-
on motif found in B12-dependent methylmalonyl-CoA mutase. J Am Chem Soc 1997;119:3057–67.
45. Gruber K, Jogl G, Klintschar G, Kratky C. High resolution crystal structures of cobalamins. In: Kra ¨utler B,
Arigoni D, Golding BT, editors. Vitamin B12 and B12 proteins Weinheim: Wiley; 1999. pp335–47.
Cobalamin in inflammation III 22546. Scheuring EM, Sagi I, Chance MR. Sulfur-containing cobalamins: x-ray absorption spectroscopic
characterization. Biochemistry 1994;33:6310–5.
47. Couture M, Stuehr DJ, Rousseau DL. The ferrous dioxygen complex of the oxygenase domain of neuronal
nitric oxide synthase. J Biol Chem 2000;275:3102–205.
48. Marletta MA, Hurshman AR, Rusche KM. Catalysis by nitric oxide synthase. Curr Opin Chem Biol
1998;2:656–63.
49. Perry JM, Marletta MA. Effects of transition metals on nitric oxide synthase catalysis. Proc Natl Acad Sci
1998;95:11101–6.
50. Kolb-Bachofen V, Kro ¨ncke K-D, Fehsel K, Suschek C. Role of inducible nitric oxide synthase in autoimmune
or other immune-mediated diseases. In: Ignarro LJ, editor. Nitric oxide: biology and pathobiology San Diego:
Academic Press; 2000. pp811–21.
51. Alderton WK, Boyham A, Lowe PN. Nitroarginine and tetrahydrobiopterin binding to the haem domain of
neuronal nitric oxide synthase using a scintillation proximity assay. Biochem J 1998;332:195–201.
52. Gardner PR. Nitric oxide dioxygenase function and mechanism of flavohemoglobin, hemoglobin, myoglobin
and their associated reductases. J Inorg Biochem 2005;99(1):247–66.
53. Helmick RA, Fletcher AE, Gardner AM, et al. Imidazole antibiotics inhibit the nitric oxide dioxygenase
function of microbial flavohemoglobin. AAC 2005;49(5):1837–43.
54. Yamashiki M, Nishimura A, Kosaka Y. Effects of methylcobalamin (vitamin B12) on in vitro cytokine
production of peripheral blood mononuclear cells. J Clin Lab Immunol 1992;37:173–82.
55. Bradbury D, Clarke D, Seedhouse C, Corbett C, Stocks J, Knox A. Vascular endothelial growth factor
induction by prostaglandin E2 in human airway smooth muscle cells is mediated by E prostanoid EP2/EP4
receptors and SpI transcription factor binding sites. J Biol Chem 2005;280:29993–30000.
56. Bauer J, Morrison BH, Grane R, et al. Effects of interferon b on transcobalamin II-receptor expression and
anti-tumor activity of nitrosylcobalamin. J Natl Cancer Inst 2002;94(13):1010–9.
57. Poydock M. Inhibiting effect of vitamins C and B12 on the mitotic activity of ascites tumours. Exp Cell Biol
1979;47:210–7.
58. Poydock ME, Harguindey S, Hart T, Takita H, Kelly D. Mitogenic inhibition and effect of survival of mice
bearing L1Z10 leukemia using a combination of dehydroascorbic acid and hydroxocobalamin. Am J Clin
Oncol 1985;8:266–9.
59. Nishizawa Y, Yamamoto T, Terada N, et al. Effects of methylcobalamin on the proliferation of androgen-
sensitive or estrogen-sensitive malignant cells in culture and in vivo. Int J Vitam Nutr Res 1997;67:164–70.
60. Tsao C, Miyashita K, Yang M. Cytotoxic activity of cobalamin in cultured malignant cells. Pathobiology
1990;58:292–6.
61. Bodian M. Neuroblastoma. Pediatr Clin North Am 1959;6:449–72.
62. Wheatley C. Multiple myeloma: the case of the .005% survivor. In: Gearin-Tosh M. Living proof, London:
Simon and Schuster.
63. Wheatley C. A unified theory of the causes of monoclonal gammopathy of unknown significance (MGUS) and
multiple myeloma, with a consequent treatment proposal for long-term control and possible cure. J Ortho
Med 2002;1:7–16.
64. Cruz T, Pastrak A. Combination therapies using vitamin B12 and therapeutic agents for treatment of viral,
proliferative and inflammatory disease. US Patent Application. Pub no.US2005/0163751 A1.
226 C. Wheatley